305 related articles for article (PubMed ID: 25748297)
21. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
[TBL] [Abstract][Full Text] [Related]
22. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
24. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up.
Beger J; Hansel G; Krönert C; Fuchs M; Tanner C; Schönlebe J; Werner C; Nowak A; Haroske G; Witzigmann H; Wollina U
Int J Dermatol; 2013 Feb; 52(2):220-30. PubMed ID: 23347311
[TBL] [Abstract][Full Text] [Related]
25. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
26. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas.
Patuzzo R; Maurichi A; Camerini T; Gallino G; Ruggeri R; Baffa G; Mattavelli I; Tinti MC; Crippa F; Moglia D; Tolomio E; Maccauro M; Santinami M
J Surg Res; 2014 Apr; 187(2):518-24. PubMed ID: 24252855
[TBL] [Abstract][Full Text] [Related]
27. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
28. Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma.
Gyorki DE; Boyle JO; Ganly I; Morris L; Shaha AR; Singh B; Wong RJ; Shah JP; Busam K; Kraus D; Coit DG; Patel S
Eur J Surg Oncol; 2014 Mar; 40(3):305-10. PubMed ID: 24361245
[TBL] [Abstract][Full Text] [Related]
29. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy.
Pearl RA; Pacifico MD; Richman PI; Wilson GD; Grover R
J Plast Reconstr Aesthet Surg; 2008; 61(3):265-71. PubMed ID: 17569608
[TBL] [Abstract][Full Text] [Related]
30. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
[TBL] [Abstract][Full Text] [Related]
32. Sentinel lymph node mapping in melanoma: the issue of false-negative findings.
Manca G; Rubello D; Romanini A; Boni G; Chiacchio S; Tredici M; Mazzarri S; Duce V; Colletti PM; Volterrani D; Mariani G
Clin Nucl Med; 2014 Jul; 39(7):e346-54. PubMed ID: 24561692
[TBL] [Abstract][Full Text] [Related]
33. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
34. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
35. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
[TBL] [Abstract][Full Text] [Related]
36. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
37. A critical reappraisal of false negative sentinel lymph node biopsy in melanoma.
Manca G; Romanini A; Rubello D; Mazzarri S; Boni G; Chiacchio S; Tredici M; Duce V; Tardelli E; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2014 Jun; 58(2):105-13. PubMed ID: 24835287
[TBL] [Abstract][Full Text] [Related]
38. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
39. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients.
Ribero S; Osella-Abate S; Sanlorenzo M; Savoia P; Astrua C; Cavaliere G; Tomasini C; Senetta R; Macripò G; Bernengo MG; Quaglino P
Br J Dermatol; 2013 Dec; 169(6):1240-5. PubMed ID: 23952011
[TBL] [Abstract][Full Text] [Related]
40. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance.
Gradilone A; Ribuffo D; Silvestri I; Cigna E; Gazzaniga P; Nofroni I; Zamolo G; Frati L; Scuderi N; Aglianò AM
Ann Surg Oncol; 2004 Nov; 11(11):983-7. PubMed ID: 15525827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
